When was ProteoGenix founded?
ProteoGenix was founded in 2002.
Where is ProteoGenix's headquarters?
ProteoGenix's headquarters is located at 3545 Howard Way, Costa Mesa.
What is ProteoGenix's latest funding round?
ProteoGenix's latest funding round is Debt.
How much did ProteoGenix raise?
ProteoGenix raised a total of $24M.
Who are the investors of ProteoGenix?
Investors of ProteoGenix include New Leaf Venture Partners, TPG Growth, Burrill & Company and Kaiser Permanente Ventures.
Who are ProteoGenix's competitors?
Competitors of ProteoGenix include Affidea, Biodesix, Signature Diagnostics, Allegro Diagnostics, Pathwork Diagnostics and 13 more.
You May Also Like
AngioLogix is a provider of cardiovascular health diagnostics.
Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.
LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.